← Research library

Cerebrolysin in amnestic mild cognitive impairment: 26-week biomarker follow-up

Observational study · 2017

What was studied
19 treated patients. Ten were grouped as stronger responders and nine as minimal or no responders after treatment.
Main finding
At week 26, MMSE changed by +2.0 versus +0.8 points in groups defined by their response after treatment. Most cognitive tests showed no significant difference between those groups.

Reported findings and study design

A single treated cohort followed to week 26 with cognitive testing and ELISA measurements of antibodies to a fragment of the p75 neurotrophin receptor.

Population or model 19 treated patients. Ten were grouped as stronger responders and nine as minimal or no responders after treatment.

Dose, route and schedule

One four-week course of 20 intravenous infusions, titrated from 5 to 10, 20 and 30 mL on the first four treatment days, then 30 mL. Assessments continued through week 26.

Protocol source ↗ · Original publisher full text, methods, cognitive and antibody results.

Results · Original publisher full text, methods, cognitive and antibody results.
MeasureResultComparison, timing and statistics
MMSE at week 26+2.0 vs +0.8 pointsStronger vs minimal or no responders, p<0.05.
Ten-word recall at week 26+0.5 vs −0.9 wordsReported p<0.05
Between-group cognitive comparisons at week 10No statistically significant differences
Change in p75-fragment antibody signalLarger decline in stronger responders at week 26Reported p<0.01

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • Everyone received Cerebrolysin. Groups were assigned using clinical and cognitive response, and differed on some baseline measures. The comparisons are exploratory.

Source details

Original publisher full text, methods, cognitive and antibody results.

Sources checked

Citation

Uncontrolled human reportFull text available

S. I. Gavrilova and colleagues. Cerebrolysin in amnestic mild cognitive impairment: 26-week biomarker follow-up Korsakov Journal of Neurology and Psychiatry. 2017;117(8):27–38.

Study source ↗ · DOI 10.17116/jnevro20171178127-38 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards